Study of a new drug combo for untreated acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia and have not yet received treatment (except possibly hydroxyurea).
- You are 65 years or older, or if younger, you are not eligible for standard intensive chemotherapy due to health issues like heart, lung, or kidney problems.
- Your overall health is generally good enough to carry out daily activities (ECOG score of 3 or less).
- Your blood counts and organ function meet certain basic standards, including having white blood cell count within a specific range.
- You do not have certain types of leukemia (like APL or those with BCR-ABL1), or if the leukemia is secondary to prior treatment or another blood disorder.
- You are not pregnant and agree to use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.